NCT06792097Not yet recruiting
Ga-68 Dolacga PET Scan in HCC Under RFA
The Role of Ga-68 Dolacga PET Scan in Patients With Hepatocellular Carcinoma Under Radiofrequency Ablation
Source: ClinicalTrials.gov · Last updated 24 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate the use of Ga-68 Dolacga PET scan technology to assess treatment response and liver function changes in patients of early-stage liver cancer receiving RFA. The main questions it aims to answer are: 1. How to assess treatment response and liver function changes in hepatocellular carcinoma patients undergo RFA via Ga-68 Dolacga PET scan? 2. Compared with computed tomography (CT) scans, how effective is Ga-68 Dolacga PET scan for treatment response assessment? 3. What is the correlation between Ga-68 Dolacga PET scan findings and patient treatment outcomes by tracking liver function and tumor recurrence after RFA? Participants will: 1. Undergo Ga-68 Dolacga PET scans and computed tomography before and one month after RFA treatment, followed by monitoring every three months thereafter. 2. Total liver functional volume and residual liver functional volume are obtained from Ga-68 Dolacga PET scan
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 10 (estimated)
- First submitted
- 19 Jan 2025
- Start date
- 1 Feb 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- National Taiwan University Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06792097
What you commit to
- Study type: Observational
- Planned participants: 10
- From 1 Feb 2025 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Early-stage liver cancer (BCLC A stage):
- Contraindications for radiofrequency ablation (RFA).
- Target lesions previously treated with local therapies, including surgical resection, percutaneous ethanol injection (PEI), or liver transplantation.
Other illness
- Intermediate (BCLC B stage) and advanced (BCLC C stage) liver cancer patients:
- A single tumor \> 5 cm, or multiple tumors \> 3 cm.
- Diffuse hepatocellular carcinoma.
- Vascular invasion (e.g., portal vein obstruction).
- Extrahepatic tumor spread.
Who the study is looking for
- Patients with hepatocellular carcinoma (BCLC stage 0 and stage A) eligible for radiofrequency ablation (RFA) treatment exhibit the following characteristics:
- A single liver tumor, ≤ 2 cm, classified as BCLC stage 0 (very early stage).
- Tumors ≤ 3 in number, each ≤ 3 cm, or a single tumor ≤ 5 cm, classified as BCLC stage A (early stage) liver cancer.
- ECOG performance status of 0.
- Age ≥ 18 years.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.